Journal of Clinical Oncology, Vol 19, Issue 8
(April), 2001: 2282-2292
© 2001 American Society for Clinical Oncology
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
By Paulo M. Hoff,
Rafat Ansari,
Gerald Batist,
John Cox,
Walter Kocha,
Mario Kuperminc,
Jean Maroun,
David Walde,
Charles Weaver,
Evelyn Harrison,
Hans U. Burger,
Bruno Osterwalder,
Alfred O. Wong,
Ralf Wong
From The University of Texas M.D. Anderson Cancer Center, Houston; Physician Reliance Network, Inc, Dallas, TX; Michiana Hematology/Oncology, South Bend, IN; Hematology and Oncology Association of Virginia, Richmond, VA; Response Oncology, Memphis, TN; Hoffmann-La Roche Inc, Nutley, NJ; McGill University Department of Oncology, Montreal, Quebec; London Regional Cancer Centre, London; Ottawa Regional Cancer Centre, Ottawa; Group Health Center, Sault Ste Marie, Ontario; Tom Baker Cancer Center, Calgary, Alberta; H. Bliss Cancer Centre, St John’s, Newfoundland, Canada; and F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Address reprint requests to Paulo M. Hoff, MD, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030-4009; email: phoff{at}mdanderson.org
PURPOSE: To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer.
PATIENTS AND METHODS: We prospectively randomized 605 patients to treatment with oral capecitabine for 14 days every 3 weeks or 5-FU/LV by rapid IV injection daily for 5 days in 4-week cycles.
RESULTS: The overall objective tumor response rate among all randomized patients was significantly higher in the capecitabine group (24.8%) than in the 5-FU/LV group (15.5%; P = .005). In the capecitabine and 5-FU/LV groups, median times to disease progression were 4.3 and 4.7 months (log-rank P = .72), median times to treatment failure were 4.1 and 3.1 months (P = .19), and median overall survival times were 12.5 and 13.3 months (P = .974), respectively. Capecitabine, compared with bolus 5-FU/LV treatment, produced a significantly lower incidence (P < .0002) of diarrhea, stomatitis, nausea, and alopecia. Patients treated with capecitabine also displayed lower incidences of grade 3/4 stomatitis and grade 3/4 neutropenia (P < .0001) leading to significantly less neutropenic fever/sepsis. Grade 3 hand-foot syndrome (P < .00001) and grade 3/4 hyperbilirubinemia were the only toxicities more frequently associated with capecitabine than with 5-FU/LV treatment.
CONCLUSION: Oral capecitabine was more active than 5-FU/LV in the induction of objective tumor responses. Time to disease progression and survival were at least equivalent for capecitabine compared with the 5-FU/LV arm. Capecitabine also demonstrated clinically meaningful benefits over bolus 5-FU/LV in terms of tolerability.
Presented in part at the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, May 15-18, 1999.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Ishida, Y. Miyake, M. Fukunaga, Y. Watanabe, T. Kato, H. Takemoto, and H. Furukawa
A Feasibility Study of UFT/LV and Irinotecan (TEGAFIRI) in Advanced or Metastatic Colorectal Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304
Jpn. J. Clin. Oncol.,
June 17, 2009;
(2009)
hyp067v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Cunningham, B. Sirohi, A. Pluzanska, B. Utracka-Hutka, J. Zaluski, R. Glynne-Jones, P. Koralewski, J. Bridgewater, P. Mainwaring, H. Wasan, et al.
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
Ann. Onc.,
February 1, 2009;
20(2):
244 - 250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. Seol, M. K. Song, Y. J. Choi, G. H. Kim, H. J. Shin, G. A. Song, J. S. Chung, and G. J. Cho
Oral Fluoropyrimidines (Capecitabine or S-1) and Cisplatin as First Line Treatment in Elderly Patients with Advanced Gastric Cancer: A Retrospective Study
Jpn. J. Clin. Oncol.,
January 1, 2009;
39(1):
43 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kolinsky, B.-Q. Shen, Y.-E Zhang, J. Kohles, U. Dugan, T. F. Zioncheck, D. Heimbrook, K. Packman, and B. Higgins
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models
Mol. Cancer Ther.,
January 1, 2009;
8(1):
75 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. KOLINSKY, Y.-E ZHANG, U. DUGAN, D. HEIMBROOK, K. PACKMAN, and B. HIGGINS
Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts
Anticancer Res,
January 1, 2009;
29(1):
91 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T. Lam, C. L. O'Bryant, M. Basche, D. L. Gustafson, N. Serkova, A. Baron, S. N. Holden, J. Dancey, S. G. Eckhardt, and L. Gore
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors
Mol. Cancer Ther.,
December 1, 2008;
7(12):
3685 - 3694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H.E. Baker, J. Lam, A. H. Kyle, J. Sy, T. Oliver, S. J. Co, W. H. Dragowska, E. Ramsay, M. Anantha, T. J. Ruth, et al.
Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin
Clin. Cancer Res.,
November 15, 2008;
14(22):
7260 - 7271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Rothenberg, J. V. Cox, C. Butts, M. Navarro, Y.-J. Bang, R. Goel, S. Gollins, L. L. Siu, S. Laguerre, and D. Cunningham
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
Ann. Onc.,
October 1, 2008;
19(10):
1720 - 1726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Laheru, G. Croghan, R. Bukowski, M. Rudek, W. Messersmith, C. Erlichman, R. Pelley, A. Jimeno, R. Donehower, J. Boni, et al.
A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer
Clin. Cancer Res.,
September 1, 2008;
14(17):
5602 - 5609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Haller, J. Cassidy, S. J. Clarke, D. Cunningham, E. Van Cutsem, P. M. Hoff, M. L. Rothenberg, L. B. Saltz, H.-J. Schmoll, C. Allegra, et al.
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
J. Clin. Oncol.,
May 1, 2008;
26(13):
2118 - 2123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cassidy, H.-J. Schmoll, and E. Van Cutsem
To the Editor
J. Clin. Oncol.,
May 1, 2008;
26(13):
2226 - 2227.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cassidy, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.-S. Yang, F. Rivera, et al.
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
J. Clin. Oncol.,
April 20, 2008;
26(12):
2006 - 2012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Chan, S. M. Ueda, V. E. Sugiyama, C. D. Stave, J. Y. Shin, B. J. Monk, B. I. Sikic, K. Osann, and D. S. Kapp
Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?
J. Clin. Oncol.,
March 20, 2008;
26(9):
1511 - 1518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. R. Norman, et al.
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
N. Engl. J. Med.,
January 3, 2008;
358(1):
36 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cassidy
Capecitabine Plus Oxaliplatin in Metastatic Colorectal Cancer
J. Clin. Oncol.,
November 1, 2007;
25(31):
5043 - 5045.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bajetta, L. Celio, E. Ferrario, M. Di Bartolomeo, A. Denaro, K. Dotti, M. Mancin, R. Bajetta, A. Colombo, and S. Pusceddu
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer
Ann. Onc.,
November 1, 2007;
18(11):
1810 - 1816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu
Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy
J. Clin. Oncol.,
October 10, 2007;
25(29):
4562 - 4568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Porschen, H.-T. Arkenau, S. Kubicka, R. Greil, T. Seufferlein, W. Freier, A. Kretzschmar, U. Graeven, A. Grothey, A. Hinke, et al.
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
J. Clin. Oncol.,
September 20, 2007;
25(27):
4217 - 4223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Diaz-Rubio, J. Tabernero, A. Gomez-Espana, B. Massuti, J. Sastre, M. Chaves, A. Abad, A. Carrato, B. Queralt, J. J. Reina, et al.
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
J. Clin. Oncol.,
September 20, 2007;
25(27):
4224 - 4230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Mayer
Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer?
J. Clin. Oncol.,
September 20, 2007;
25(27):
4165 - 4167.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol.,
May 10, 2007;
25(14):
1832 - 1843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin,
May 1, 2007;
57(3):
168 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Meropol and K. A. Schulman
Cost of Cancer Care: Issues and Implications
J. Clin. Oncol.,
January 10, 2007;
25(2):
180 - 186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Koopman, N. Antonini, J Douma, J Wals, A. Honkoop, F. Erdkamp, R. de Jong, C. Rodenburg, G Vreugdenhil, J. Akkermans-Vogelaar, et al.
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
Ann. Onc.,
October 1, 2006;
17(10):
1523 - 1528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. H. O'Neil and H. L. McLeod
Thymidine Phosphorylase and Capecitabine: A Predictive Marker for Therapy Selection?
J. Clin. Oncol.,
September 1, 2006;
24(25):
4051 - 4053.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Meropol, P. J. Gold, R. B. Diasio, M. Andria, M. Dhami, T. Godfrey, A. J. Kovatich, K. A. Lund, E. Mitchell, and R. Schwarting
Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol.,
September 1, 2006;
24(25):
4069 - 4077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M Gressett, B. L Stanford, and F. Hardwicke
Management of hand-foot syndrome induced by capecitabine
Journal of Oncology Pharmacy Practice,
September 1, 2006;
12(3):
131 - 141.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Wan, D. Cao, J. Zeng, R. Yan, and G. Pizzorno
Modulation of Uridine Phosphorylase Gene Expression by Tumor Necrosis Factor-{alpha} Enhances the Antiproliferative Activity of the Capecitabine Intermediate 5'-Deoxy-5-fluorouridine in Breast Cancer Cells
Mol. Pharmacol.,
April 1, 2006;
69(4):
1389 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Kohne and G. Folprecht
On prejudice and facts and choices
Ann. Onc.,
February 1, 2006;
17(2):
185 - 187.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Saif, M. A. Eloubeidi, S. Russo, A. Steg, J. Thornton, J. Fiveash, M. Carpenter, C. Blanquicett, R. B. Diasio, and M. R. Johnson
Phase I Study of Capecitabine With Concomitant Radiotherapy for Patients With Locally Advanced Pancreatic Cancer: Expression Analysis of Genes Related to Outcome
J. Clin. Oncol.,
December 1, 2005;
23(34):
8679 - 8687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry
Cardiotoxicity of Cancer Therapy
J. Clin. Oncol.,
October 20, 2005;
23(30):
7685 - 7696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sakamoto, C. Hamada, M. Rahman, S. Kodaira, K. Ito, H. Nakazato, Y. Ohashi, and M. Yasutomi
An Individual Patient Data Meta-analysis of Adjuvant Therapy with Carmofur in Patients with Curatively Resected Colon Cancer
Jpn. J. Clin. Oncol.,
September 1, 2005;
35(9):
536 - 544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Wasil and S. M. Lichtman
Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Oncologist,
September 1, 2005;
10(8):
602 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Andre and W Schmiegel
CHEMORADIOTHERAPY FOR COLORECTAL CANCER
Gut,
August 1, 2005;
54(8):
1194 - 1202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. T. Hennessy, A. M. Gauthier, L. B. Michaud, G. Hortobagyi, and V. Valero
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
Ann. Onc.,
August 1, 2005;
16(8):
1289 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kelly and R. M. Goldberg
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
J. Clin. Oncol.,
July 10, 2005;
23(20):
4553 - 4560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Rea, J. W. R. Nortier, W. W. Ten Bokkel Huinink, S. Falk, D. J. Richel, T. Maughan, G. Groenewegen, J. M. Smit, N. Steven, J. M. Bakker, et al.
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
Ann. Onc.,
July 1, 2005;
16(7):
1123 - 1132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.P. Kalofonos, G. Aravantinos, P. Kosmidis, P. Papakostas, T. Economopoulos, M. Dimopoulos, D. Skarlos, A. Bamias, D. Pectasides, S. Chalkidou, et al.
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
Ann. Onc.,
June 1, 2005;
16(6):
869 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Feliu, P. Escudero, F. Llosa, M. Bolanos, J.-M. Vicent, A. Yubero, J.-J. Sanz-Lacalle, R. Lopez, L. Lopez-Gomez, E. Casado, et al.
Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study
J. Clin. Oncol.,
May 1, 2005;
23(13):
3104 - 3111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hurwitz
New Combinations in Metastatic Colorectal Cancer: What Are Our Expectations?
Oncologist,
May 1, 2005;
10(5):
320 - 322.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Venook
Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Oncologist,
April 1, 2005;
10(4):
250 - 261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Poplin, J. K. Benedetti, N. C. Estes, D. G. Haller, R. J. Mayer, R. M. Goldberg, G. R. Weiss, S. E. Rivkin, and J. S. Macdonald
Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer
J. Clin. Oncol.,
March 20, 2005;
23(9):
1819 - 1825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol.,
March 10, 2005;
23(8):
1760 - 1775.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Meyerhardt and R. J. Mayer
Systemic Therapy for Colorectal Cancer
N. Engl. J. Med.,
February 3, 2005;
352(5):
476 - 487.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Borner, J. Bernhard, D. Dietrich, R. Popescu, M. Wernli, P. Saletti, D. Rauch, R. Herrmann, D. Koeberle, H. Honegger, et al.
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Ann. Onc.,
February 1, 2005;
16(2):
282 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Michael and M.M. Doherty
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
J. Clin. Oncol.,
January 1, 2005;
23(1):
205 - 229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. A. Punt
New options and old dilemmas in the treatment of patients with advanced colorectal cancer
Ann. Onc.,
October 1, 2004;
15(10):
1453 - 1459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. S. Heo, H. M. Chang, T. W. Kim, M.-H. Ryu, J.-H. Ahn, S. B. Kim, J. S. Lee, W. K. Kim, H. K. Cho, and Y.-K. Kang
Hand-Foot Syndrome in Patients Treated With Capecitabine-Containing Combination Chemotherapy
J. Clin. Pharmacol.,
October 1, 2004;
44(10):
1166 - 1172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Crane and D. J. Sargent
Substitution of Oral Fluoropyrimidines for Infusional Fluorouracil With Radiotherapy: How Much Data Do We Need?
J. Clin. Oncol.,
August 1, 2004;
22(15):
2978 - 2981.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Lee, T. M. Kim, S. J. Yu, D.-W. Kim, Y.-h. Joh, D.-Y. Oh, J. H. Kwon, T. Y. Kim, D. S. Heo, Y.-J. Bang, et al.
Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy
Jpn. J. Clin. Oncol.,
July 1, 2004;
34(7):
400 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Hoff, R. Pazdur, Y. Lassere, S. Carter, D. Samid, D. Polito, and J. L. Abbruzzese
Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal Carcinoma
J. Clin. Oncol.,
June 1, 2004;
22(11):
2078 - 2083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cassidy, J. Tabernero, C. Twelves, R. Brunet, C. Butts, T. Conroy, F. Debraud, A. Figer, J. Grossmann, N. Sawada, et al.
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
J. Clin. Oncol.,
June 1, 2004;
22(11):
2084 - 2091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Rich, R. C. Shepard, and S. T. Mosley
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
J. Clin. Oncol.,
June 1, 2004;
22(11):
2214 - 2232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Diaz-Rubio
New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers
Oncologist,
June 1, 2004;
9(3):
282 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Saltz, N. J. Meropol, P. J. Loehrer Sr, M. N. Needle, J. Kopit, and R. J. Mayer
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
J. Clin. Oncol.,
April 1, 2004;
22(7):
1201 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Grothey, D. Sargent, R. M. Goldberg, and H.-J. Schmoll
Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment
J. Clin. Oncol.,
April 1, 2004;
22(7):
1209 - 1214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials
J. Clin. Oncol.,
February 1, 2004;
22(3):
484 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Gilbar
Palmar-plantar erythrodysesthesia
Journal of Oncology Pharmacy Practice,
December 1, 2003;
9(4):
137 - 150.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. E Mortimer, M. K. Lauman, B. Tan, C. L Dempsey, A. C Shillington, and K. S Hutchins
Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine
Journal of Oncology Pharmacy Practice,
December 1, 2003;
9(4):
161 - 166.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. W. M. van Laarhoven, D. W. J. Klomp, Y. J. L. Kamm, C. J. A. Punt, and A. Heerschap
In Vivo Monitoring of Capecitabine Metabolism in Human Liver by 19Fluorine Magnetic Resonance Spectroscopy at 1.5 and 3 Tesla Field Strength
Cancer Res.,
November 15, 2003;
63(22):
7609 - 7612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zeuli, C. Nardoni, M. S. Pino, T. Gamucci, A. Gabriele, V. Ferraresi, D. Giannarelli, and F. Cognetti
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
Ann. Onc.,
September 1, 2003;
14(9):
1378 - 1382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tewes, N. Schleucher, W. Achterrath, H. J. Wilke, S. Frings, S. Seeber, A. Harstrick, Y. M. Rustum, and U. Vanhoefer
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study{dagger}
Ann. Onc.,
September 1, 2003;
14(9):
1442 - 1448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Scheithauer, G. V. Kornek, M. Raderer, B. Schull, K. Schmid, E. Kovats, B. Schneeweiss, F. Lang, A. Lenauer, and D. Depisch
Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
J. Clin. Oncol.,
April 1, 2003;
21(7):
1307 - 1312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gennatas, C. Dardoufas, D. Mouratidou, N. Tsavaris, A. Pouli, G. Androulakis, M. Philippakis, D. Voros, T. Batalis, S. Besbeas, et al.
Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-{alpha}2b
Ann. Onc.,
March 1, 2003;
14(3):
378 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Hoff, E. D. Saad, J. A. Ajani, Y. Lassere, C. Wenske, D. Medgyesy, S. Dwivedy, M. Russo, and R. Pazdur
Phase I Study with Pharmacokinetics of S-1 on an Oral Daily Schedule for 28 Days in Patients with Solid Tumors
Clin. Cancer Res.,
January 1, 2003;
9(1):
134 - 142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Chau and D. Cunningham
Chemotherapy in colorectal cancer: new options and new challenges
Br. Med. Bull.,
December 1, 2002;
64(1):
159 - 180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. W. Kim, Y. K. Kang, J. H. Ahn, H. M. Chang, J. H. Yook, S. T. Oh, B. S. Kim, and J. S. Lee
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer
Ann. Onc.,
December 1, 2002;
13(12):
1893 - 1898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Scheithauer, G. V. Kornek, M. Raderer, B. Schull, K. Schmid, F. Langle, and H. Huber
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer
Ann. Onc.,
October 1, 2002;
13(10):
1583 - 1589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dunst, T. Reese, T. Sutter, H. Zuhlke, A. Hinke, K. Kolling-Schlebusch, and S. Frings
Phase I Trial Evaluating the Concurrent Combination of Radiotherapy and Capecitabine in Rectal Cancer
J. Clin. Oncol.,
October 1, 2002;
20(19):
3983 - 3991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-S. Yang, J.-Y. Wang, R. Tang, K.-C. Hsu, and J.-S. Chen
Oral Uracil/Ftorafur (UFT) Plus Leucovorin as First-line Chemotherapy and Salvage Therapy with Weekly High-dose 5-Fluorouracil/Leucovorin for the Treatment of Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol.,
September 1, 2002;
32(9):
352 - 357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. J. Evans, G. Pentheroudakis, J. Paul, A. McInnes, R. Blackie, N. Raby, R. Morrison, G. M. Fullarton, M. Soukop, and A. C. McDonald
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma
Ann. Onc.,
September 1, 2002;
13(9):
1469 - 1478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-Y. Douillard, P. M. Hoff, J. R. Skillings, P. Eisenberg, N. Davidson, P. Harper, M. D. Vincent, B. C. Lembersky, S. Thompson, A. Maniero, et al.
Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
J. Clin. Oncol.,
September 1, 2002;
20(17):
3605 - 3616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Carmichael, T. Popiela, D. Radstone, S. Falk, M. Borner, A. Oza, T. Skovsgaard, S. Munier, and C. Martin
Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
J. Clin. Oncol.,
September 1, 2002;
20(17):
3617 - 3627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malet-Martino and R. Martino
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
Oncologist,
August 1, 2002;
7(4):
288 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Leslie and R J C Steele
Management of colorectal cancer
Postgrad. Med. J.,
August 1, 2002;
78(922):
473 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Borner, D. Dietrich, R. Stupp, R. Morant, H. Honegger, M. Wernli, R. Herrmann, B. C. Pestalozzi, P. Saletti, S. Hanselmann, et al.
Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer
J. Clin. Oncol.,
April 1, 2002;
20(7):
1759 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Diaz-Rubio, T. R. J. Evans, J. Tabernero, J. Cassidy, J. Sastre, M. Eatock, D. Bisset, P. Regueiro, and J. Baselga
Capecitabine (Xeloda(R)) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
Ann. Onc.,
April 1, 2002;
13(4):
558 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cassidy, C. Twelves, E. Van Cutsem, P. Hoff, E. Bajetta, M. Boyer, R. Bugat, U. Burger, A. Garin, U. Graeven, et al.
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
Ann. Onc.,
April 1, 2002;
13(4):
566 - 575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Macdonald
Vive La Difference: Sex and Fluorouracil Toxicity
J. Clin. Oncol.,
March 15, 2002;
20(6):
1439 - 1441.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Van Cutsem, P. M. Hoff, J. L. Blum, M. Abt, and B. Osterwalder
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil
Ann. Onc.,
March 1, 2002;
13(3):
484 - 485.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Diasio
An Evolving Role for Oral Fluoropyrimidine Drugs
J. Clin. Oncol.,
February 15, 2002;
20(4):
894 - 896.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bleiberg, A. Di Leo, M. L. Rothenberg, N. J. Meropol, E. A. Poplin, E. Van Cutsem, and S. Wadler
Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin
J. Clin. Oncol.,
February 15, 2002;
20(4):
1145 - 1146.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Cartwright, A. Cohn, J. A. Varkey, Y.-M. Chen, T. P. Szatrowski, J. V. Cox, and J. J. Schulz
Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer
J. Clin. Oncol.,
January 1, 2002;
20(1):
160 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Summerhayes
Capecitabine: a novel, orally administered, tumour-activated treatment for colorectal cancer
Journal of Oncology Pharmacy Practice,
December 1, 2001;
7(4):
107 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Mayer
Oral Versus Intravenous Fluoropyrimidines for Advanced Colorectal Cancer: By Either Route, It's All the Same
J. Clin. Oncol.,
November 1, 2001;
19(21):
4093 - 4096.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, M. Jahn, et al.
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study
J. Clin. Oncol.,
November 1, 2001;
19(21):
4097 - 4106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Hoff, J. Cassidy, and H.-J. Schmoll
The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral
Oncologist,
August 1, 2001;
6(2008):
3 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
